ERBB2 and lymphangioma: To demonstrate how this model could be used to study novel HER2 directed therapies and to characterize the sensitivity of the NT2.5-LM model, NT2.5-LM metastasis-bearing mice were treated with anti-HER2 antibody by intraperitoneal (i.p.)injection once a week and assessed for survival (Fig. S5).